Ampio Pharmaceuticals (AMPE) 10-Q 10 May 19 2019 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 01, 2019
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q1
Entity Registrant Name	Ampio Pharmaceuticals, Inc.
Entity Central Index Key	0001411906
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Trading Symbol	AMPE
Entity Common Stock, Shares Outstanding		111,127,878
Entity Small Business	true
Entity Emerging Growth Company	false

Balance Sheets

Balance Sheets - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Current assets
Cash and cash equivalents	$ 5,160,070	$ 7,585,392
Prepaid expenses and other	593,404	413,280
Total current assets	5,753,474	7,998,672
Fixed assets, net (Note 3)	5,677,632	5,997,582
Deposits	33,856	33,856
Right-of-use asset (Note 5)	1,127,825	0
Total assets	12,592,787	14,030,110
Current liabilities
Accounts payable and accrued expenses	1,278,523	1,324,651
Accrued compensation	41,486	0
Lease liability - current portion (Note 5)	241,144	59,579
Total current liabilities	1,561,153	1,384,230
Long-term lease liability (Note 5)	1,407,054	476,753
Warrant derivative liability	10,092,563	6,933,031
Total liabilities	13,060,770	8,794,014
Commitments and contingencies (Note 5)
Stockholders' equity
Preferred Stock, par value $0.0001; 10,000,000 shares authorized; none issued
Common Stock, par value $0.0001; 200,000,000 shares authorized; shares issued and outstanding - 111,127,878 in March 31, 2019 (unaudited) and 110,941,516 in December 31, 2018	11,113	11,094
Additional paid-in capital	176,335,046	176,227,510
Accumulated deficit	(176,814,142)	(171,002,508)
Total stockholders’ (deficit) equity	(467,983)	5,236,096
Total liabilities and stockholders' equity	$ 12,592,787	$ 14,030,110

Balance Sheets (Parenthetical)

Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred Stock, par value	$ 0.0001	$ 0.0001
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Common Stock, par value	$ 0.0001	$ 0.0001
Common Stock, shares authorized	200,000,000	200,000,000
Common Stock, shares issued	111,127,878	110,941,516
Common Stock, shares outstanding	111,127,878	110,941,516

Statements of Operations

Statements of Operations - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Operating expenses
Research and development	$ 1,564,178	$ 2,044,476
General and administrative	1,111,689	1,530,357
Total operating expenses	2,675,867	3,574,833
Other income (expense)
Interest income	23,765	0
Derivative (loss) gain (Note 4)	(3,159,532)	25,614,305
Total other (expense) income	(3,135,767)	25,614,305
Net (loss) income	$ (5,811,634)	$ 22,039,472
Basic and diluted net (loss) income per common share	$ (0.05)	$ 0.27
Weighted average number of common shares outstanding	111,104,292	82,943,340

Statements of Stockholders' Equ

Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Beginning Balance at Dec. 31, 2017	$ 8,006	$ 170,803,783	$ (204,988,674)	$ (34,176,885)
Beginning Balance, shares at Dec. 31, 2017	80,060,345
Issuance of common stock for services (unaudited)	$ 2	59,998	0	60,000
Issuance of common stock for services (unaudited) (Shares)	17,241
Options exercised, net (unaudited)	$ 25	400,734	0	400,759
Options exercised, net (unaudited) (Shares)	249,666
Warrants exercised, net (unaudited)	$ 568	2,699,651	0	2,700,219
Warrants exercised, net (unaudited) (Shares)	5,684,499
Stock-based compensation, net (unaudited)	$ 0	119,623	0	119,623
Net (loss) income	0	0	22,039,472	22,039,472
Ending Balance at Mar. 31, 2018	$ 8,601	174,083,789	(182,949,202)	(8,856,812)
Ending Balance, shares at Mar. 31, 2018	86,011,751
Beginning Balance at Dec. 31, 2017	$ 8,006	170,803,783	(204,988,674)	(34,176,885)
Beginning Balance, shares at Dec. 31, 2017	80,060,345
Ending Balance at Dec. 31, 2018	$ 11,094	176,227,510	(171,002,508)	5,236,096
Ending Balance, shares at Dec. 31, 2018	110,941,516
Issuance of common stock for services (unaudited)	$ 14	59,986	0	60,000
Issuance of common stock for services (unaudited) (Shares)	136,362
Warrants exercised, net (unaudited)	$ 5	19,995	0	20,000
Warrants exercised, net (unaudited) (Shares)	50,000
Stock-based compensation, net (unaudited)	$ 0	27,555	0	27,555
Net (loss) income	0	0	(5,811,634)	(5,811,634)
Ending Balance at Mar. 31, 2019	$ 11,113	$ 176,335,046	$ (176,814,142)	$ (467,983)
Ending Balance, shares at Mar. 31, 2019	111,127,878

Statements of Cash Flows

Statements of Cash Flows - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Cash flows from operating activities
Net (loss) income	$ (5,811,634)	$ 22,039,472
Adjustments to reconcile net (loss) income to net cash used in operating activities
Stock-based compensation and warrant modification	27,555	119,623
Depreciation and amortization	365,050	300,884
Issuance of common stock for services	60,000	60,000
Derivative loss (gain) (Note 4)	3,159,532	(25,614,305)
Changes in operating assets and liabilities
Increase in prepaid expenses and other	(180,124)	(152,766)
Decrease in accounts payable and accrued expenses	(46,128)	(292,581)
Decrease in lease liability (Note 5)	(55,955)	(13,540)
Increase (decrease) in accrued compensation	41,486	(50,812)
Net cash used in operating activities	(2,440,218)	(3,604,025)
Cash flows used in investing activities
Purchase of fixed assets	(5,104)	(188,548)
Net cash used in investing activities	(5,104)	(188,548)
Cash flows from financing activities
Proceeds from option and warrant exercises	20,000	3,100,978
Net cash provided by financing activities	20,000	3,100,978
Net change in cash and cash equivalents	(2,425,322)	(691,595)
Cash and cash equivalents at beginning of period	7,585,392	8,209,071
Cash and cash equivalents at end of period	5,160,070	7,517,476
Non-cash transactions:
Lease liability arising from obtaining right-of-use asset (Note 5)	1,704,153	0
Initial recognition of right-of-use asset (Note 5)	$ 1,167,821	$ 0

Basis of Presentation

Basis of Presentation	3 Months Ended
	Mar. 31, 2019
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 - Basis of Presentation The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information and with the instructions of the Securities and Exchange Commission (“SEC”) on Quarterly Reports on Form 10‑Q and Rule 10‑01 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, the financial statements include all adjustments necessary, which are of a normal and recurring nature, for the fair presentation of the financial position and of the results of operations and cash flows of Ampio Pharmaceuticals, Inc. (“Ampio” or the “Company”) for the periods presented. These financial statements should be read in conjunction with the audited financial statements and notes thereto for the year ended December 31, 2018 included in the Company’s Annual Report on Form 10‑K filed with the SEC on March 18, 2019 (the “2018 Annual Report”). The results of operations for the interim period shown in this report are not necessarily indicative of the results that may be expected for any other interim period or for the full year. The balance sheet at December 31, 2018 was derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for complete financial statements. Ampio is a biopharmaceutical company primarily focused on developing Ampion, which is a compound that decreases inflammation by inhibiting specific pro-inflammatory compounds. Ampio’s activities are primarily related to research and development and raising capital. The Company has not generated revenue to date. Adoption of Recent Accounting Pronouncements In May 2017, the FASB issued Accounting Standards Update (“ASU 2017‑09,”) “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting”. ASU 2017-09 provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. For all entities, this standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2017‑09 during the first quarter of 2018 and the adoption of this guidance did not have a material impact on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. Lessees are required to use a modified retrospective transition approach for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” to clarify how to apply certain aspects of the new lease standard. In July 2018, the FASB also issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements”, to give entities other options for transition. The additional options for transition allow an entity to apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption or apply a practical expedient. The new standards are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company elected to adopt the practical expedient permitted by ASU 2018-11 during the first quarter of 2019. As a result of the adoption, on January 1, 2019, the Company recognized a lease liability of approximately $1.7 million, which represents the present value of the remaining minimum lease payments using an estimated incremental borrowing rate of 5.75%. The Company also derecognized the deferred rent balance, which included deferred tenant improvements, as of December 31, 2018 of approximately $540,000 and recognized an ROU asset of approximately $1.2 million. Lease expense did not change materially as a result of the adoption of ASU 2016-02. In June 2018, the FASB issued ASU 2018‑07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” . ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions used to acquire goods and services from nonemployees. Companies should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those fiscal years. Early adoption is permitted, but no earlier than the Company’s adoption date of ASU 2014‑09 “ Revenue from Contracts with Customers (Topic 606)” . The Company adopted ASU 2018‑07 during the first quarter of 2019 and the adoption of this guidance did not have a material impact on the Company’s financial statements as all outstanding non-employee share-based awards have fully vested. In July 2018, the FASB issued ASU 2018-09, “Codification Improvements” , which facilitates amendments to a variety of topics to clarify, correct errors in, or make minor improvements to the accounting standards codification. The effective date of the standard is dependent on the facts and circumstances of each amendment. Some amendments do not require transition guidance and will be effective upon the issuance of this standard. A majority of the amendments in ASU 2018-09 will be effective for fiscal years beginning after December 15, 2018. The Company adopted ASU 2018-09 during the first quarter of 2019 and the adoption of this guidance did not have a material impact on the Company’s financial statements. Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018‑13, “ Fair Value Measurement - Disclosure Framework (Topic 820) ”. The updated guidance improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years beginning after December 15, 2019, including interim reporting periods within those fiscal years. Early adoption is permitted for any removed or modified disclosures. The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Going Concern

Going Concern	3 Months Ended
	Mar. 31, 2019
Going Concern [Abstract]
Going Concern	Note 2 - Going Concern As reflected in the accompanying financial statements, the Company had cash and cash equivalents of $5.2 million as of March 31, 2019 with net loss of $5.8 million for the three months ended March 31, 2019. The net loss is primarily attributable to the non-cash derivative loss of $3.1 million that was recognized, along with operating expenses of $2.7 million during the period ended March 31, 2019. The Company used net cash in operations of $2.4 million for the period ended March 31, 2019. As of March 31, 2019, the Company ended with an accumulated deficit of $176.8 million and stockholders’ deficit of $0.5 million. In addition, the Company is a clinical stage biopharmaceutical company and has not generated any revenues or profits to date. These factors raise substantial doubt about the Company’s ability to continue as a going concern. During the three months ending March 31, 2019, the Company received a total of $20,000 from the exercise of investor warrants (see Note 7 ). The Company prepared a budget for 2019, which reflects cash requirements for fixed, on-going expenses such as payroll, legal and accounting, patents and overhead at an average cash burn rate of approximately $0.7 million per month. Additional funds are planned for regulatory approvals, clinical trials, outsourced research and development and commercialization consulting. Ampio expects that current cash resources and operating cash flows will be sufficient to sustain operations into the second quarter of 2019. The ability of the Company to continue its operations is dependent on management’s plans, which include continuing to raise equity-based and debt financing, as well as encouraging additional warrant exercises. However, there is no assurance that the Company will be successful in raising sufficient capital to continue its operations. The accompanying unaudited interim financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

Fixed Assets

Fixed Assets	3 Months Ended
	Mar. 31, 2019
Fixed Assets [Abstract]
Fixed Assets	Note 3 - Fixed Assets Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease terms. Fixed assets consist of the following: Estimated As of March 31, As of December 31, Useful Lives in Years 2019 2018 Manufacturing facility/clean room 3 - 8 $ 3,082,000 $ 3,076,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 5 - 10 511,000 511,000 Lab equipment 5 - 8 1,128,000 1,128,000 Less accumulated depreciation and amortization (5,118,000) (4,793,000) Fixed assets, net $ 5,678,000 $ 5,997,000 Depreciation expense for the respective periods is as follows: Three Months Ended March 31, 2019 2018 Depreciation Expense $ 325,000 $ 301,000

Fair Value Considerations

Fair Value Considerations	3 Months Ended
	Mar. 31, 2019
Fair Value Considerations [Abstract]
Fair Value Considerations	Note 4 - Fair Value Considerations Authoritative guidance defines fair value as the price that would be received upon the sale of an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. The guidance establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of Ampio. Unobservable inputs are inputs that reflect the Company’s assumptions of what market participants would use in pricing the asset or liability based on the best information available in the circumstances. The hierarchy is broken down into three levels based on reliability of the inputs as follows: Level 1: Inputs that reflect unadjusted quoted prices in active markets that are accessible to Ampio for identical assets or liabilities; Level 2: Inputs include quoted prices for similar assets and liabilities in active or inactive markets or that are observable for the asset or liability either directly or indirectly; and Level 3: Unobservable inputs that are supported by little or no market activity. The Company’s financial instruments include cash and cash equivalents, accounts payable and accrued expenses, and warrant derivative liability. The carrying amounts of cash and cash equivalents and accounts payable and accrued expenses are carried at cost, which approximates fair value due to the short maturity of these instruments. Warrants are recorded at estimated fair value based on a Black-Scholes warrant pricing model. The valuation policies are determined by the Chief Financial Officer and approved by the Company’s Board of Directors. The following table presents Ampio’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2019 and December 31, 2018, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2019 LIABILITIES Warrant derivative liability $ — $ — $ 10,093,000 $ 10,093,000 December 31, 2018 LIABILITIES Warrant derivative liability $ — $ — $ 6,933,000 $ 6,933,000 The warrant derivative liability was valued using the Black-Scholes valuation methodology because that model embodies all the relevant assumptions that address the features underlying these instruments. The significant assumptions in valuing the warrant derivative liability as of March 31, 2019 and at issuance are disclosed in Note 7 . The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: Derivative Instruments Balance as of December 31, 2018 $ 6,933,000 Warrant exercises (24,000) Change in fair value 3,184,000 Balance as of March 31, 2019 $ 10,093,000

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Litigation [Abstract]
Commitments and Contingencies	Note 5 - Commitments and Contingencies Commitments and contingencies are described below and summarized by the following table: Total 2019 2020 2021 2022 2023 Thereafter Clinical research and trial obligations 6,162,000 6,162,000 — — — — — Biologics License Application ("BLA") consulting services 1,135,000 1,135,000 — — — — — Facility lease 1,925,000 246,000 335,000 345,000 355,000 364,000 280,000 $ 9,222,000 $ 7,543,000 $ 335,000 $ 345,000 $ 355,000 $ 364,000 $ 280,000 Clinical Research and Trial Obligations In March 2019, the Company entered into a contract with a clinical research organization in connection with the upcoming clinical trial for Ampion, which has an outstanding commitment of $6.2 million. When the trial commences, the Company will pay an upfront payment of $0.9 million, which is expected to be paid during the second quarter of 2019. Biologics License Application (“BLA”) Consulting Services In March 2018, Ampio entered into a BLA consulting services agreement, which has an outstanding commitment of $1.1 million. This contract is an open-ended contract and the Company incurs costs as sections of the BLA are drafted for the complete submission of the BLA to the U.S. Food and Drug Administration (“FDA”). The Company has incurred $77,000 against the contract as of March 31, 2019. Facility Lease In December 2013, Ampio entered into a 125-month non-cancellable operating lease for office space and a manufacturing facility. The effective date for the lease was May 1, 2014. The initial base rent of the lease was $23,000 per month. The total base rent over the term of the lease is approximately $3.3 million, which includes rent abatements and leasehold incentives. As discussed within Note 1 , the Company adopted the FASB issued ASU 2016-02, “Leases (Topic 842)” as of January 1, 2019. With the adoption of ASU 2016-02, the Company recorded an operating right-of-use asset and an operating lease liability on the balance sheet. The right-of-use asset represents the Company’s right to use the underlying asset for the lease term and the lease obligation represents the Company’s commitment to make the lease payments arising from the lease. Right-of-use lease assets and obligations are recognized at the commencement date based on the present value of remaining lease payments over the lease term. As the Company’s lease does not provide an implicit rate, the Company used an estimated incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. Rent expense is recognized on a straight-line basis over the lease term, subject to any changes in the lease or expectations regarding the terms. The lease liability is classified between current and long-term on the balance sheet. The following table provides a reconciliation of the Company’s undiscounted payments for its facility lease and the carrying amount of the lease liability presented in the balance sheet as of March 31, 2019: Facility Lease Payments Remaining Facility Lease Payments $ 1,925,000 Less: Discount Adjustment (277,000) Total lease liability 1,648,000 Lease liability - current portion 241,000 Long-term lease liability 1,407,000 Amortization expense related to the right-of-use asset for the respective periods is as follows: Three Months Ended March 31, 2019 2018 Right-of-use Asset Amortization Expense $ 40,000 $ — Prior to the adoption of ASU 2016-02, the Company recognized deferred rent when the straight-line rent expense exceeded the actual lease payments and reduced deferred rent when the actual lease payments exceeded the straight-line rent expense. Deferred rent was also classified between current and long-term on the balance sheet. Rent expense for the respective periods is as follows: Three Months Ended March 31, 2019 2018 Rent expense $ 66,000 $ 65,000

Common Stock

Common Stock	3 Months Ended
	Mar. 31, 2019
Common Stock [Abstract]
Common Stock	Note 6 - Common Stock Shelf Registration In March 2017, Ampio filed a shelf registration statement on Form S‑3 (the “Shelf Registration Statement”) with the SEC to register Ampio common stock and warrants in an aggregate amount of up to $100.0 million for offerings from time to time, as well as 5.0 million shares of common stock available for sale by selling shareholders. The Shelf Registration Statement was declared effective in April 2017 by the SEC and expires in March 2020. As a result of equity raises, approximately $78.7 million remained available under the Shelf Registration Statement as of March 31, 2019. However, under current SEC regulations, if at the time the Company files its Annual Report on Form 10-K (“Form 10-K”), the Company’s public float is less than $75 million, and for so long as its non-affiliated public float is less than $75 million, the amount the Company can raise through primary public offerings of securities in any twelve-month period using its Shelf Registration Statement is limited to an aggregate of one-third of the Company’s non-affiliated public float, which is referred to as the baby shelf rules. As of March 31, 2019, the Company’s non-affiliated public float was approximately $73.97 million, based on 108,778,659 shares of outstanding common stock held by non-affiliates at a price of $0.68 per share, which was the last reported sale price of the Company’s common stock on the NYSE American Market on March 4, 2019. As a result of the Company’s non-affiliated public float being below $75 million, the Company will be limited by the baby shelf rules until such time as the Company’s non-affiliated public float exceeds $75 million. If the Company’s public float decreases for a subsequent public offering, the amount of securities the Company may sell under its Shelf Registration Statement will also decline. As of March 31, 2019, the Company had the capacity to issue up to $24.65 million worth of shares under the baby shelf rules. Confidentially Marketed Public Offering In August 2018, the Company completed a confidentially marketed public offering. In this offering, the Company issued 20.0 million shares of its common stock and warrants to purchase up to 20.0 million shares of common stock. The common stock and warrants were sold in units, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock. Each unit was sold to the investors at a negotiated price of $0.40 per unit generating gross proceeds of $8.0 million. In connection with the offering, the underwriter received a 7% commission totaling $560,000. The Company also incurred expenses related to legal, accounting, and other registration costs of $284,000. The shares and the warrants were offered and sold pursuant to the Company’s Shelf Registration Statement. The warrants have an exercise price of $0.40 per share and were exercisable immediately with a term of five years from issuance. The warrants include a provision where the warrant holder has the contractual right to request a cash exercise if the effectiveness of the registration statement is not maintained, but securities law would prevent the Company from issuing registered shares in a cash exercise. Therefore, the Company could be forced to settle the warrants in cash. Based on this derivative feature, these warrants must be accounted for as a liability at fair value under Accounting Standards Codification 815 “Derivatives and Hedging”. On the date of issuance, these warrants were valued at $8.0 million. The Company’s net cash proceeds from the confidentially marketed public offering totaled $7.2 million. When the additional non-cash charges of $8.0 million related to the 20.0 million warrants are offset against the net cash proceeds from the transaction, the non-cash charges exceeded 100% of the proceeds. Therefore, the Company was required to take the additional cost above the transaction proceeds and recognize a loss on the day it entered into the transaction. The loss on the transaction was $0.9 million and this amount was offset by the derivative gain on the statement of operations. Controlled Equity Offering In February 2016, Ampio entered into a Controlled Equity Offering SM Sales Agreement (the “Controlled Equity Offering Agreement”) with a placement agent to implement an “at-the-market” equity program under which Ampio, from time to time could offer and sell shares of its common stock having an aggregate offering price of up to $25.0 million through the placement agent. The Company had no obligation to sell any of the shares and could at any time suspend sales under the Controlled Equity Offering Agreement or terminate the Controlled Equity Offering Agreement in accordance with its terms. The Company provided the placement agent with customary indemnification rights. The placement agent was entitled to a fixed commission of 3.0% of the gross proceeds from shares sold. In April 2019, the Company terminated this Controlled Equity Offering Agreement. No shares were sold under the Controlled Equity Offering Agreement during fiscal 2018 or the three months ended March 31, 2019. In April 2019, the Company entered into an Equity Distribution Agreement with a placement agent to implement an “at-the-market” equity program under which the Company, from time to time may offer and sell shares of its common stock, having an aggregate offering price of up to $24.65 million (the “Shares”) through the placement agent. The Company has no obligation to sell any of the Shares and may at any time suspend sales under the Equity Distribution Agreement or terminate the Equity Distribution Agreement in accordance with its terms. The Company has provided the placement agent with customary indemnification rights. The placement agent will be entitled to a fixed commission of 3.0% of the gross proceeds from shares sold. Future sales will depend on a variety of factors including, but not limited to, market conditions, the trading price of the Company’s common stock and the Company’s capital needs. There can be no assurance that the Company’s placement agent will be successful in consummating future sales based on prevailing market conditions or in the quantities or at the prices the Company deems appropriate. Common Stock Issued for Services Ampio issued 136,362 and 17,241 shares of common stock valued at $60,000 and $60,000, respectively, to non-employee directors as part of their director compensation for fiscal years 2019 and 2018, respectively.

Equity Instruments

Equity Instruments	3 Months Ended
	Mar. 31, 2019
Equity Instruments [Abstract]
Equity Instruments	Note 7 - Equity Instruments Options In 2010, Ampio shareholders approved the adoption of a stock and option award plan (the “2010 Plan”), under which shares were reserved for future issuance under restricted stock awards, options and other equity awards. The 2010 Plan permits grants of equity awards to employees, directors and consultants. The shareholders have approved a total of 11.7 million shares reserved for issuance under the 2010 Plan. During the three months ended March 31, 2019, the Company did not grant options to officers, directors or employees. There were also no option exercises or forfeitures during the three months ended March 31, 2019. The following table summarizes Ampio’s stock option activity: Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Price Contractual Life Intrinsic Value Outstanding at December 31, 2018 5,426,165 $ 1.99 4.89 $ — Granted — $ — Exercised — $ — Forfeited — $ — Expired or Cancelled — $ — Outstanding at March 31, 2019 5,426,165 $ 1.99 4.65 $ 53,814 Exercisable at March 31, 2019 5,171,996 $ 2.06 4.46 $ 41,789 Available for grant at March 31, 2019 4,229,783 Stock options outstanding at March 31, 2019 are summarized in the table below: Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives $0.48 - $2.00 3,293,423 $ 0.82 5.61 $2.01 - $5.00 1,750,000 $ 3.07 2.99 $5.01 - $8.62 382,742 $ 7.13 3.97 5,426,165 $ 1.99 4.65 The Company computes the fair value for all options granted or modified using the Black-Scholes option pricing model. To calculate the fair value of the options, certain assumptions are made regarding components of the model, including the fair value of the underlying common stock, risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company calculates its volatility assumption using the actual changes in the market value of its stock. Forfeitures are recognized as they occur. The Company’s historical option exercises do not provide a reasonable basis to estimate an expected term due to the lack of sufficient data. Therefore, the Company estimates the expected term by using the simplified method. The simplified method calculates the expected term as the average of the vesting term plus the contractual life of the options. The risk-free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for treasury securities of similar maturity. The Company did not utilize any assumptions during the quarter as no options were granted during the period ended March 31, 2019. Stock-based compensation expense related to the fair value of stock options is included in the statements of operations as research and development expenses or general and administrative expenses as set forth in the table below. The following table summarizes stock-based compensation expense for the three months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 2018 Research and development expenses Stock-based compensation $ 500 $ 23,000 General and administrative expenses Issuance of common stock for services 60,000 60,000 Stock-based compensation 27,000 96,000 Total stock-based compensation $ 87,500 $ 179,000 Unrecognized expense at March 31, 2019 41,000 Weighted average remaining years to vest 0.75 Warrants In connection with the August 2018 confidentially marketed public offering, Ampio issued warrants to purchase an aggregate of 20.0 million shares of common stock at an exercise price of $0.40 with a term of five years. Due to certain derivative features, these warrants are accounted for under liability accounting and are recorded at fair value each reporting period. As of March 31, 2019, these warrants had a fair value of $7.5 million. Significant assumptions as of March 31, 2019, December 31, 2018 and at issuance were as follows: Assumptions for warrants issued August 13, 2018: March 31, 2019 December 31, 2018 At Issuance Exercise Price $ 0.40 $ 0.40 $ 0.40 Volatility 130.2 % 129.8 % 121.8 % Equivalent term (years) 4.37 4.62 5.00 Risk-free interest rate 2.22 % 2.50 % 2.75 % Number of shares 15,500,000 15,600,000 20,000,000 The total value for the warrant liability as of March 31, 2019 is $10.1 million, which includes warrant issuances from prior periods. See Note 4 for additional information regarding the warrant derivative liability. During the three months ended March 31, 2019, the Company issued 50,000 shares of common stock from the exercise of investor warrants with an exercise price of $0.40 from the 2018 confidentially marketed public offering. The Company received $20,000 as of March 31, 2019 related to these investor warrant exercises. The following table summarizes Ampio’s warrant activity: Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding at December 31, 2018 22,283,191 $ 0.51 4.25 Warrants exercised (50,000) $ 0.40 Outstanding at March 31, 2019 22,233,191 $ 0.51 4.00

Litigation

Litigation	3 Months Ended
	Mar. 31, 2019
Litigation [Abstract]
Litigation	Note 8 – Litigation On August 25, 2018, a purported shareholder of the Company commenced a putative class action lawsuit in the United States District Court for the Central District of California, captioned Shi v. Ampio Pharmaceuticals, Inc., et al. , Case No. 18-cv-07476 (the “Securities Class Action”). A second, similar class action was filed on August 31, 2018, but has since been voluntarily dismissed. Plaintiff in the Securities Class Action alleges that the Company and certain of its current officers violated the federal securities laws by misrepresenting and/or omitting material information regarding the AP-003 Phase III clinical trials of Ampion. The plaintiff asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and Securities and Exchange Commission Rule 10b-5, on behalf of a putative class of purchasers of the Company’s common stock from December 14, 2017 through August 7, 2018. Plaintiff in the Securities Class Action seeks unspecified damages, pre-judgment and post-judgment interest, and attorneys’ fees and costs. On September 10, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the Central District of California, captioned Cetrone v. Macaluso, et al. , Case No. 18-cv-07855 (the “Cetrone Action”), alleging primarily that the directors and officers of Ampio breached their fiduciary duties in connection with alleged misstatements and omissions regarding the AP-003 Phase III clinical trials of Ampion. On October 5, 2018, a purported stockholder of the Company brought a derivative action in the United States District Court for the District of Colorado, Theise v. Macaluso, et al. , Case No. 18-cv-02558 (the “Theise Action”), which closely parallels the allegations in the Cetrone Action. A second derivative action was filed in the United States District Court for the District of Colorado and was consolidated with the Theise Action under the caption In re: Ampio Pharmaceuticals Inc. Stockholder Derivative Actions , Case No. 18-cv-02558. The Company believes the claims asserted in each of these actions are meritless and intends to defend against these lawsuits vigorously. The Company currently believes the likelihood of a loss contingency related to these matters is remote and, therefore, no provision for a loss contingency is required.

Subsequent Events

Subsequent Events	3 Months Ended
	Mar. 31, 2019
Subsequent Events [Abstract]
Subsequent Events	Note 9 - Subsequent Events See Note 6 for information regarding the Equity Distribution Agreement that the Company entered into in April 2019 and the termination of the Controlled Equity Offering Agreement that occurred during April 2019. As of May 10, 2019, the Company has raised gross proceeds of $142,300 through the Equity Distribution Agreement. In connection with the offering, the Company paid a 3% placement fee totaling $4,300, resulting of net proceeds of $138,000. In April 2019, the Company granted 70,500 options to fifteen employees. In April 2019, the Company received a subpoena from the SEC requesting documents in an investigation relating to the trading of its securities. The Company is cooperating with the inquiry. The Company is, at this time, unable to predict what action, if any, might be taken in the future by the SEC as a result of the matters that are the subject of the subpoena. Subsequent to the evaluation of the effectiveness of the design and operation of the Company’s disclosure controls and procedures as of March 31, 2019, the Company identified a material weakness relating to identification of information for appropriate disclosure. The material weakness relates to a deficiency in the procedures in place to ensure disclosure of certain information to our Disclosure Committee. The Disclosure Committee intends to review this matter and implement appropriate controls.

Basis of Presentation (Policies

Basis of Presentation (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Recent Accounting Pronouncements	Adoption of Recent Accounting Pronouncements In May 2017, the FASB issued Accounting Standards Update (“ASU 2017‑09,”) “Compensation-Stock Compensation (Topic 718): Scope of Modification Accounting”. ASU 2017-09 provides guidance on determining which changes to the terms and conditions of share-based payment awards require an entity to apply modification accounting under Topic 718. Under the new guidance, modification accounting is required only if the fair value, the vesting conditions, or the classification of the award changes as a result of the change in terms or conditions. For all entities, this standard is effective for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. The Company adopted ASU 2017‑09 during the first quarter of 2018 and the adoption of this guidance did not have a material impact on the Company’s financial statements. In February 2016, the FASB issued ASU 2016-02, “Leases (Topic 842)” . The new standard establishes a right-of-use (“ROU”) model that requires a lessee to record a ROU asset and a lease liability on the balance sheet for all leases with terms longer than 12 months. Leases will be classified as either finance or operating, with classification affecting the pattern of expense recognition in the income statement. Lessees are required to use a modified retrospective transition approach for capital and operating leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” to clarify how to apply certain aspects of the new lease standard. In July 2018, the FASB also issued ASU 2018-11, “Leases (Topic 842): Targeted Improvements”, to give entities other options for transition. The additional options for transition allow an entity to apply the new lease standard at the adoption date and recognize a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption or apply a practical expedient. The new standards are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. The Company elected to adopt the practical expedient permitted by ASU 2018-11 during the first quarter of 2019. As a result of the adoption, on January 1, 2019, the Company recognized a lease liability of approximately $1.7 million, which represents the present value of the remaining minimum lease payments using an estimated incremental borrowing rate of 5.75%. The Company also derecognized the deferred rent balance, which included deferred tenant improvements, as of December 31, 2018 of approximately $540,000 and recognized an ROU asset of approximately $1.2 million. Lease expense did not change materially as a result of the adoption of ASU 2016-02. In June 2018, the FASB issued ASU 2018‑07, “Compensation-Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting” . ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions used to acquire goods and services from nonemployees. Companies should apply the requirements of Topic 718 to nonemployee awards except for certain exemptions specified in the amendment. The guidance is effective for fiscal years beginning after December 15, 2018, including interim reporting periods within those fiscal years. Early adoption is permitted, but no earlier than the Company’s adoption date of ASU 2014‑09 “ Revenue from Contracts with Customers (Topic 606)” . The Company adopted ASU 2018‑07 during the first quarter of 2019 and the adoption of this guidance did not have a material impact on the Company’s financial statements as all outstanding non-employee share-based awards have fully vested. In July 2018, the FASB issued ASU 2018-09, “Codification Improvements” , which facilitates amendments to a variety of topics to clarify, correct errors in, or make minor improvements to the accounting standards codification. The effective date of the standard is dependent on the facts and circumstances of each amendment. Some amendments do not require transition guidance and will be effective upon the issuance of this standard. A majority of the amendments in ASU 2018-09 will be effective for fiscal years beginning after December 15, 2018. The Company adopted ASU 2018-09 during the first quarter of 2019 and the adoption of this guidance did not have a material impact on the Company’s financial statements. Recent Accounting Pronouncements In August 2018, the FASB issued ASU 2018‑13, “ Fair Value Measurement - Disclosure Framework (Topic 820) ”. The updated guidance improves the disclosure requirements on fair value measurements. The updated guidance is effective for fiscal years beginning after December 15, 2019, including interim reporting periods within those fiscal years. Early adoption is permitted for any removed or modified disclosures. The Company does not expect the adoption of this ASU will have a significant impact on its financial statements. The Company does not discuss recent pronouncements that are not anticipated to have an impact on or are unrelated to its financial condition, results of operations, cash flows or disclosures.

Fixed Assets (Tables)

Fixed Assets (Tables)	3 Months Ended
	Mar. 31, 2019
Fixed Assets [Abstract]
Schedule of Fixed Assets	Fixed assets are recorded at cost and, once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease terms. Fixed assets consist of the following: Estimated As of March 31, As of December 31, Useful Lives in Years 2019 2018 Manufacturing facility/clean room 3 - 8 $ 3,082,000 $ 3,076,000 Leasehold improvements 10 6,075,000 6,075,000 Office furniture and equipment 5 - 10 511,000 511,000 Lab equipment 5 - 8 1,128,000 1,128,000 Less accumulated depreciation and amortization (5,118,000) (4,793,000) Fixed assets, net $ 5,678,000 $ 5,997,000
Schedule Of Depreciation And Amortization Expense	Depreciation expense for the respective periods is as follows: Three Months Ended March 31, 2019 2018 Depreciation Expense $ 325,000 $ 301,000

Fair Value Considerations (Tabl

Fair Value Considerations (Tables)	3 Months Ended
	Mar. 31, 2019
Fair Value Considerations [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table presents Ampio’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2019 and December 31, 2018, by level within the fair value hierarchy: Fair Value Measurements Using Level 1 Level 2 Level 3 Total March 31, 2019 LIABILITIES Warrant derivative liability $ — $ — $ 10,093,000 $ 10,093,000 December 31, 2018 LIABILITIES Warrant derivative liability $ — $ — $ 6,933,000 $ 6,933,000
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation	The following table sets forth a reconciliation of changes in the fair value of financial liabilities classified as Level 3 in the fair value hierarchy: Derivative Instruments Balance as of December 31, 2018 $ 6,933,000 Warrant exercises (24,000) Change in fair value 3,184,000 Balance as of March 31, 2019 $ 10,093,000

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Litigation [Abstract]
Summary of Commitments and Contingencies	Commitments and contingencies are described below and summarized by the following table: Total 2019 2020 2021 2022 2023 Thereafter Clinical research and trial obligations 6,162,000 6,162,000 — — — — — Biologics License Application ("BLA") consulting services 1,135,000 1,135,000 — — — — — Facility lease 1,925,000 246,000 335,000 345,000 355,000 364,000 280,000 $ 9,222,000 $ 7,543,000 $ 335,000 $ 345,000 $ 355,000 $ 364,000 $ 280,000
Summary of reconciliation of the Company’s undiscounted payments for its facility lease and the carrying amount of the lease liability	The following table provides a reconciliation of the Company’s undiscounted payments for its facility lease and the carrying amount of the lease liability presented in the balance sheet as of March 31, 2019: Facility Lease Payments Remaining Facility Lease Payments $ 1,925,000 Less: Discount Adjustment (277,000) Total lease liability 1,648,000 Lease liability - current portion 241,000 Long-term lease liability 1,407,000
Amortization expense related to the right-of-use asset	Amortization expense related to the right-of-use asset for the respective periods is as follows: Three Months Ended March 31, 2019 2018 Right-of-use Asset Amortization Expense $ 40,000 $ —
Rent Expense	the Company recognized deferred rent when the straight-line rent expense exceeded the actual lease payments and reduced deferred rent when the actual lease payments exceeded the straight-line rent expense. Deferred rent was also classified between current and long-term on the balance sheet. Rent expense for the respective periods is as follows: Three Months Ended March 31, 2019 2018 Rent expense $ 66,000 $ 65,000

Equity Instruments (Tables)

Equity Instruments (Tables)	3 Months Ended
	Mar. 31, 2019
Stock Option Activity	The following table summarizes Ampio’s stock option activity: Weighted Weighted Average Number of Average Remaining Aggregate Options Exercise Price Contractual Life Intrinsic Value Outstanding at December 31, 2018 5,426,165 $ 1.99 4.89 $ — Granted — $ — Exercised — $ — Forfeited — $ — Expired or Cancelled — $ — Outstanding at March 31, 2019 5,426,165 $ 1.99 4.65 $ 53,814 Exercisable at March 31, 2019 5,171,996 $ 2.06 4.46 $ 41,789 Available for grant at March 31, 2019 4,229,783
Summary of Stock Options Outstanding and Exercisable	Stock options outstanding at March 31, 2019 are summarized in the table below: Number of Weighted Weighted Average Options Average Remaining Range of Exercise Prices Outstanding Exercise Price Contractual Lives $0.48 - $2.00 3,293,423 $ 0.82 5.61 $2.01 - $5.00 1,750,000 $ 3.07 2.99 $5.01 - $8.62 382,742 $ 7.13 3.97 5,426,165 $ 1.99 4.65
Summary of Stock-Based Compensation Expense	The following table summarizes stock-based compensation expense for the three months ended March 31, 2019 and 2018: Three Months Ended March 31, 2019 2018 Research and development expenses Stock-based compensation $ 500 $ 23,000 General and administrative expenses Issuance of common stock for services 60,000 60,000 Stock-based compensation 27,000 96,000 Total stock-based compensation $ 87,500 $ 179,000 Unrecognized expense at March 31, 2019 41,000 Weighted average remaining years to vest 0.75
Summary of Company's warrant activity	The following table summarizes Ampio’s warrant activity: Weighted Weighted Average Number of Average Remaining Warrants Exercise Price Contractual Life Outstanding at December 31, 2018 22,283,191 $ 0.51 4.25 Warrants exercised (50,000) $ 0.40 Outstanding at March 31, 2019 22,233,191 $ 0.51 4.00
Confidentially Marketed Public Offering | August 2018 Warrants [Member]
Schedule of assumptions for warrants issued	Significant assumptions as of March 31, 2019, December 31, 2018 and at issuance were as follows: Assumptions for warrants issued August 13, 2018: March 31, 2019 December 31, 2018 At Issuance Exercise Price $ 0.40 $ 0.40 $ 0.40 Volatility 130.2 % 129.8 % 121.8 % Equivalent term (years) 4.37 4.62 5.00 Risk-free interest rate 2.22 % 2.50 % 2.75 % Number of shares 15,500,000 15,600,000 20,000,000

Basis of Presentation - Additio

Basis of Presentation - Additional Information (Detail) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Present value of remaining minimum lease payments	$ 1,925,000
Incremental borrowing rate	5.75%
Derecognized Deferred Rent	$ 540,000
Operating Lease, Right-of-Use Asset	1,127,825	$ 0
ASU 2016-02 | Restatement Adjustment
Present value of remaining minimum lease payments	1,700,000
Operating Lease, Right-of-Use Asset	$ 1,200,000

Going Concern - Additional Info

Going Concern - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Dec. 31, 2017
Cash and Cash Equivalents, at Carrying Value	$ 5,160,070		$ 7,585,392
Net Income (Loss) Attributable to Parent	(5,811,634)	$ 22,039,472
Gain (Loss) on Derivative Instruments, Net, Pretax	(3,159,532)	25,614,305
Operating Expenses	2,675,867	3,574,833
Net Cash Provided by (Used in) Operating Activities	(2,440,218)	(3,604,025)
Retained Earnings (Accumulated Deficit)	(176,814,142)		(171,002,508)
Stockholders' deficit	(467,983)	(8,856,812)	$ 5,236,096	$ (34,176,885)
Stock Issued During Period, Value, Stock Options Exercised		$ 400,759
Cash requirements for fixed, on-going expenses such as payroll, legal and accounting, patents and overhead at an average cash burn rate	700,000
Warrant to purchase shares of common stock [Member]
Stock Issued During Period, Value, Stock Options Exercised	$ 20,000

Fixed Assets (Detail)

Fixed Assets (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Less accumulated depreciation and amortization	$ (5,118,000)	$ (4,793,000)
Fixed assets, net	5,677,632	5,997,582
Manufacturing Facility/ clean room [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 3,082,000	3,076,000
Manufacturing Facility/ clean room [Member] | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	3 years
Manufacturing Facility/ clean room [Member] | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 6,075,000	6,075,000
Estimated useful lives	10 years
Office Furniture And Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 511,000	511,000
Office Furniture And Equipment [Member] | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Office Furniture And Equipment [Member] | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	10 years
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Fixed assets, gross	$ 1,128,000	$ 1,128,000
Lab Equipment [Member] | Minimum
Property, Plant and Equipment [Line Items]
Estimated useful lives	5 years
Lab Equipment [Member] | Maximum
Property, Plant and Equipment [Line Items]
Estimated useful lives	8 years

Fixed Assets - Depreciation and

Fixed Assets - Depreciation and Amortization Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Fixed Assets [Abstract]
Depreciation and Amortization Expense	$ 325,000	$ 301,000

Fair Value Considerations - Fin

Fair Value Considerations - Financial Assets and Liabilities (Detail) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
LIABILITIES
Warrant derivative liability	$ 10,092,563	$ 6,933,031
Fair Value, Inputs, Level 1 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
LIABILITIES
Warrant derivative liability	0	0
Fair Value, Inputs, Level 3 [Member]
LIABILITIES
Warrant derivative liability	$ 10,093,000	$ 6,933,000

Fair Value Considerations - Set

Fair Value Considerations - Sets Forth a Reconciliation of Changes (Detail)	3 Months Ended
	Mar. 31, 2019USD ($)
Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Abstract]
Balance as of December 31, 2018	$ 6,933,000
Warrants exercises	(24,000)
Change in fair value	3,184,000
Balance as of March 31, 2019	$ 10,093,000

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Jun. 30, 2019	Mar. 31, 2018	Dec. 31, 2013
Commitments and Contingencies [Line Items]
Contractual obligation	$ 9,222,000
Newly Leased Office Space and Manufacturing Facility [Member]
Commitments and Contingencies [Line Items]
Non-cancellable operating lease period				125 months
Non-cancellable operating lease effective date	May 1, 2014
Lessee, Operating Lease, Term of Contract				125 months
Lease initial base rent per month	$ 23,000
Total base rent over the term of the lease	3,300,000
Clinical research and trial obligations [Member]
Commitments and Contingencies [Line Items]
Contractual obligation	6,162,000
Other Commitment	6,200,000
Clinical research and trial obligations [Member] | Forecast
Commitments and Contingencies [Line Items]
Contractual obligation		$ 900,000
Biologics License Application (BLA) consulting services [Member]
Commitments and Contingencies [Line Items]
Contractual obligation			$ 1,100,000
Amount Incurred Against Contract Obligation	$ 77,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Commitments and Contingencies (Detail)	Mar. 31, 2019USD ($)
Commitment And Contingencies [Line Items]
Total	$ 9,222,000
2019	7,543,000
2020	335,000
2021	345,000
2022	355,000
2023	364,000
Thereafter	280,000
Clinical research and trial obligations [Member]
Commitment And Contingencies [Line Items]
Total	6,162,000
2019	6,162,000
2021	0
2022	0
2023	0
Thereafter	0
Biologics License Application (BLA) consulting services [Member]
Commitment And Contingencies [Line Items]
Total	1,135,000
2019	1,135,000
2021	0
2022	0
2023	0
Thereafter	0
Facility lease [Member]
Commitment And Contingencies [Line Items]
Total	1,925,000
2019	246,000
2020	335,000
2021	345,000
2022	355,000
2023	364,000
Thereafter	$ 280,000

Commitments and Contingencies_3

Commitments and Contingencies - Summary of Reconciliation of Company’s Undiscounted Payments for Facility Lease and Carrying Amount of Lease Liability (Detail) - USD ($)	Mar. 31, 2019	Dec. 31, 2018
Operating Lease Liabilities, Payments Due [Abstract]
Remaining Facility Lease Payments	$ 1,925,000
Less: Discount Adjustment	(277,000)
Total lease liability	1,648,000
Lease liability - current portion	241,144	$ 59,579
Long-term lease liability	$ 1,407,054	$ 476,753

Commitments and Contingencies_4

Commitments and Contingencies - Rent Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Litigation [Abstract]
Right-of-use Asset Amortization Expense	$ 40,000
Rent expense	$ 66,000	$ 65,000

Common Stock (Shelf Registratio

Common Stock (Shelf Registration Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended
	Mar. 31, 2017	Mar. 31, 2019	Dec. 31, 2018
Components Of Common Stock [Line Items]
Shares of outstanding common stock held by non-affiliates		111,127,878	110,941,516
Shelf Registration
Components Of Common Stock [Line Items]
Common stock and warrants	$ 100,000
Common stock to be sold by directors and management in future public offerings	5,000,000
Remaining common stocks and warrants under shelf registration		$ 78,700
Non-affiliated public float		$ 73,970
Shares of outstanding common stock held by non-affiliates		108,778,659
Share price		$ 0.68
Maximum aggregate offering price of equity securities		$ 24,650

Common Stock (Confidentially Ma

Common Stock (Confidentially Marketed Public Offering Narrative) (Details) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	May 10, 2019	Dec. 31, 2018	Aug. 13, 2018
Components Of Common Stock [Line Items]
Percentage of commission				3.00%
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 0.51			$ 0.51
Gain (Loss) on Derivative Instruments, Net, Pretax		$ (3,159,532)	$ 25,614,305
August 2018 Warrants [Member] | Confidentially Marketed Public Offering
Components Of Common Stock [Line Items]
Issuance of common stock (Shares)	20,000,000	50,000
Warrants to purchase common stock, shares	20,000,000
Negotiated price per unit	$ 0.40
Proceeds from issuance of common stock	$ 8,000,000
Percentage of commission	7.00%
Underwriter commission	$ 560,000
Costs associated with the offering	$ 284,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 0.40	$ 0.40
Warrant, Term	5 years	4 years 4 months 13 days			4 years 7 months 13 days	5 years
Warrants and Rights Outstanding	$ 8,000,000
Net proceeds from issuance of common stock	7,200,000
Non Cash Charges	$ 8,000,000
Percentage of non cash charges exceeding, net cash proceeds (in percent)	100.00%
Gain (Loss) on Derivative Instruments, Net, Pretax	$ 900,000

Common Stock (Controlled Equity

Common Stock (Controlled Equity Offering) (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018	May 10, 2019	Apr. 30, 2019	Feb. 29, 2016
Components Of Common Stock [Line Items]
Percentage of commission			3.00%
Controlled Equity Offering Agreement
Components Of Common Stock [Line Items]
Issuance of common stock (Shares)	0	0
Percentage of commission				3.00%	3.00%
Maximum aggregate offering price of equity securities				$ 24,650	$ 25,000

Common Stock (Common Stock Issu

Common Stock (Common Stock Issued for Services) (Details) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Components Of Common Stock [Line Items]
Stock Issued During Period, Value, Issued for Services	$ 60,000	$ 60,000
Common Stock Issued for Services [Member] | Non Employee Directors
Components Of Common Stock [Line Items]
Stock Issued During Period, Shares, Issued for Services	136,362	17,241
Stock Issued During Period, Value, Issued for Services	$ 60,000	$ 60,000

Equity Instruments - Options, A

Equity Instruments - Options, Additional Information (Detail) shares in Millions	Dec. 31, 2010shares
2010 Stock Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares reserved for issuance	11.7

Equity Instruments - Stock Opti

Equity Instruments - Stock Option Activity (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Number of Options
Number of Options, Beginning Balance	5,426,165
Number of Options, Ending Balance	5,426,165	5,426,165
Number of Options, Exercisable	5,171,996
Number of Options, Available for grant	4,229,783
Weighted Average Exercise Price
Weighted Average Exercise Price, Beginning Balance	$ 1.99
Weighted Average Exercise Price, Ending Balance	1.99	$ 1.99
Weighted Average Exercise Price, Exercisable	$ 2.06
Weighted Average Remaining Contractual Life, Outstanding	4 years 7 months 24 days	4 years 10 months 21 days
Weighted Average Remaining Contractual Life, Exercisable	4 years 5 months 16 days
Aggregate Intrinsic Value, Outstanding	$ 53,814
Aggregate Intrinsic Value, Exercisable	$ 41,789

Equity Instruments - Summary of

Equity Instruments - Summary of Stock Options Outstanding and Exercisable (Detail)	3 Months Ended
	Mar. 31, 2019$ / sharesshares
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	5,426,165
Weighted Average Exercise Price	$ 1.99
Weighted Average Remaining Contractual Lives	4 years 7 months 24 days
$0.48 - $2.00[Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	3,293,423
Weighted Average Exercise Price	$ 0.82
Range of Exercise Prices Lower	0.48
Range of Exercise Prices Upper	$ 2
Weighted Average Remaining Contractual Lives	5 years 7 months 10 days
$2.01 - $5.00 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	1,750,000
Weighted Average Exercise Price	$ 3.07
Range of Exercise Prices Lower	2.01
Range of Exercise Prices Upper	$ 5
Weighted Average Remaining Contractual Lives	2 years 11 months 27 days
$5.01 - $8.93 [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Number of Options Outstanding | shares	382,742
Weighted Average Exercise Price	$ 7.13
Range of Exercise Prices Lower	5.01
Range of Exercise Prices Upper	$ 8.62
Weighted Average Remaining Contractual Lives	3 years 11 months 19 days

Equity Instruments - Summary _2

Equity Instruments - Summary of Stock-Based Compensation Expense (Detail) - USD ($)	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized expense at March 31, 2019	$ 41,000
Weighted average remaining years to vest	9 months
Research and Development Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 500	$ 23,000
General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	87,500	179,000
General and Administrative Expenses [Member] | Common Stock Issued for Services [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	60,000	60,000
General and Administrative Expenses [Member] | Stock Based Compensation [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock-based compensation expenses	$ 27,000	$ 96,000

Equity Instruments - Warrants,

Equity Instruments - Warrants, Additional Information (Detail) - USD ($)	1 Months Ended	3 Months Ended
	Aug. 31, 2018	Mar. 31, 2019	Dec. 31, 2018	Aug. 13, 2018
Class of Warrant or Right [Line Items]
Warrants, Exercise price		$ 0.51	$ 0.51
Warrant derivative liability		$ 10,092,563	$ 6,933,031
Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Proceeds for the investor warrant exercise		$ 20,000
Confidentially Marketed Public Offering | August 2018 Warrants [Member]
Class of Warrant or Right [Line Items]
Warrants to purchase common stock, shares	20,000,000
Warrants, Exercise price	$ 0.40	$ 0.40
Warrant, Term	5 years	4 years 4 months 13 days	4 years 7 months 13 days	5 years
Warrants outstanding, Fair value		$ 7,500,000
Issuance of common stock (Shares)	20,000,000	50,000

Equity Instruments - Assumption

Equity Instruments - Assumptions for Warrants Issued (Detail)	Mar. 31, 2019Rate$ / sharesshares	Dec. 31, 2018Rate$ / sharesshares	Aug. 31, 2018	Aug. 13, 2018Rate$ / sharesshares
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Number of shares	22,233,191	22,283,191
August 2018 Warrants [Member] | Confidentially Marketed Public Offering
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Equivalent term (years)	4 years 4 months 13 days	4 years 7 months 13 days	5 years	5 years
Number of shares	15,500,000	15,600,000		20,000,000
August 2018 Warrants [Member] | Confidentially Marketed Public Offering | Measurement Input, Exercise Price [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input | $ / shares	0.40	0.40		0.40
August 2018 Warrants [Member] | Confidentially Marketed Public Offering | Measurement Input, Price Volatility [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input	130.2	129.8		121.8
August 2018 Warrants [Member] | Confidentially Marketed Public Offering | Measurement Input, Risk Free Interest Rate [Member]
Fair Value Measurement Inputs and Valuation Techniques [Line Items]
Warrants and Rights Outstanding, Measurement Input | Rate	2.22	2.50		2.75

Equity Instruments - Warrants I

Equity Instruments - Warrants Issued in Conjunction with its Senior Convertible Debentures (Detail) - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Number of Warrants Outstanding
Number of Warrants Outstanding, Beginning Balance	22,283,191
Number of Warrants, Warrants exercised	(50,000)
Number of Warrants Outstanding, Ending Balance	22,233,191	22,283,191
Warrants, Weighted Average Exercise Price
Weighted Average Exercise Price, Outstanding Beginning Balance	$ 0.51
Weighted Average Exercise Price, Warrants exercised	0.40
Weighted Average Exercise Price, Outstanding Ending Balance	$ 0.51	$ 0.51
Weighted Average Remaining Contractual Life
Weighted Average Remaining Contractual Life, Warrants Outstanding	4 years	4 years 3 months

Subsequent Events - (Detail)

Subsequent Events - (Detail) - USD ($)	May 10, 2019	Apr. 30, 2019
Subsequent Event [Line Items]
Percentage of commission	3.00%
Subsequent Event | Equity Distribution Agreement
Subsequent Event [Line Items]
Gross proceeds from issuance of common stock	$ 142,300
Underwriter commission	4,300
Net proceeds from issuance of common stock	$ 138,000
Subsequent Event | Employee Stock Option
Subsequent Event [Line Items]
Number of Options, Granted		70,500